Supernus 2Q loss widens as it preps drug launch
09:17 EDT 10 Aug 2012 | PharmPro
Supernus Pharmaceuticals Inc.'s second-quarter loss grew as revenue fell and operating expenses rose while the specialty drugmaker prepared to launch the epilepsy treatment Trokendi XR.The Rockville, Md., company raised $47.6 million with an initial..
Original Article: Supernus 2Q loss widens as it preps drug launch
More From BioPortfolio on "Supernus 2Q loss widens as it preps drug launch"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
